DE102018007480A1 - Medicinal or nutritional supplements for maintaining the health of brain cells and / or treating damaged brain cells by activating the cell metabolism of the brain cells and / or for preventive protection by increasing the antioxidant concentration in the brain. - Google Patents
Medicinal or nutritional supplements for maintaining the health of brain cells and / or treating damaged brain cells by activating the cell metabolism of the brain cells and / or for preventive protection by increasing the antioxidant concentration in the brain. Download PDFInfo
- Publication number
- DE102018007480A1 DE102018007480A1 DE102018007480.4A DE102018007480A DE102018007480A1 DE 102018007480 A1 DE102018007480 A1 DE 102018007480A1 DE 102018007480 A DE102018007480 A DE 102018007480A DE 102018007480 A1 DE102018007480 A1 DE 102018007480A1
- Authority
- DE
- Germany
- Prior art keywords
- weight
- medicinal
- brain cells
- brain
- nutritional supplement
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 19
- 210000004958 brain cell Anatomy 0.000 title claims abstract description 18
- 230000003213 activating effect Effects 0.000 title abstract description 5
- 239000003963 antioxidant agent Substances 0.000 title abstract description 5
- 210000004556 brain Anatomy 0.000 title abstract description 5
- 230000036541 health Effects 0.000 title abstract description 5
- 230000019522 cellular metabolic process Effects 0.000 title abstract description 4
- 230000003449 preventive effect Effects 0.000 title abstract description 4
- 230000003078 antioxidant effect Effects 0.000 title description 2
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 9
- 239000011707 mineral Substances 0.000 claims abstract description 9
- 239000000419 plant extract Substances 0.000 claims abstract description 5
- 102000008186 Collagen Human genes 0.000 claims description 14
- 108010035532 Collagen Proteins 0.000 claims description 14
- 229920001436 collagen Polymers 0.000 claims description 14
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 13
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims description 13
- 229960002591 hydroxyproline Drugs 0.000 claims description 13
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims description 13
- HMMGKOVEOFBCAU-BCDBGHSCSA-N 3-Acetyl-11-keto-beta-boswellic acid Chemical compound C1C[C@@H](OC(C)=O)[C@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C)[C@H](C)[C@H]5C4=CC(=O)[C@@H]3[C@]21C HMMGKOVEOFBCAU-BCDBGHSCSA-N 0.000 claims description 6
- HMMGKOVEOFBCAU-UHFFFAOYSA-N AKBA Natural products C1CC(OC(C)=O)C(C)(C(O)=O)C2CCC3(C)C4(C)CCC5(C)CCC(C)C(C)C5C4=CC(=O)C3C21C HMMGKOVEOFBCAU-UHFFFAOYSA-N 0.000 claims description 6
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 241000219318 Amaranthus Species 0.000 claims description 5
- 241000208317 Petroselinum Species 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 5
- 235000011197 perejil Nutrition 0.000 claims description 5
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims description 4
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 4
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 4
- 235000013793 astaxanthin Nutrition 0.000 claims description 4
- 239000001168 astaxanthin Substances 0.000 claims description 4
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims description 4
- 229940022405 astaxanthin Drugs 0.000 claims description 4
- 235000021283 resveratrol Nutrition 0.000 claims description 4
- 229940016667 resveratrol Drugs 0.000 claims description 4
- 235000012754 curcumin Nutrition 0.000 claims description 3
- 239000004148 curcumin Substances 0.000 claims description 3
- 229940109262 curcumin Drugs 0.000 claims description 3
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 3
- 235000013311 vegetables Nutrition 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 239000008121 dextrose Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 239000004615 ingredient Substances 0.000 abstract description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 45
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 229910002651 NO3 Inorganic materials 0.000 description 3
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 3
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- ODUCDPQEXGNKDN-UHFFFAOYSA-N Nitrogen oxide(NO) Natural products O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010078321 Guanylate Cyclase Proteins 0.000 description 1
- 102000014469 Guanylate cyclase Human genes 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 102100022397 Nitric oxide synthase, brain Human genes 0.000 description 1
- 101710111444 Nitric oxide synthase, brain Proteins 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000007959 normoxia Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Arznei- oder Nahrungsergänzungsmittel zur Aufrechterhaltung der Gesundheit von Gehirnzellen und/oder der Behandlung von geschädigten Gehirnzellen durch Aktivierung des Zellstoffwechsels der Gehirnzellen und/oder zum präventiven Schutz durch Erhöhung der Antioxidantien Konzentration im Gehirn, die eine Kombination aus Zutaten mit hoher Bioverfügbarkeit und einem in einer speziellen Form vorliegenden Mineralstoff- und Pflanzenextrakt-Mix aufweisen.Medicinal or nutritional supplements for maintaining the health of brain cells and / or treating damaged brain cells by activating the cell metabolism of the brain cells and / or for preventive protection by increasing the concentration of antioxidants in the brain, which is a combination of ingredients with high bioavailability and one in one special form of mineral and plant extract mix present.
Description
Die Erfindung betrifft ein Arznei- oder Nahrungsergänzungsmittel zur Aufrechterhaltung der Gesundheit von Gehirnzellen und/oder der Behandlung von geschädigten Gehirnzellen durch Aktivierung des Zellstoffwechsels der Gehirnzellen und/oder zum präventiven Schutz durch Erhöhung der Antioxidantien Konzentration im Gehirn, die eine Kombination aus Zutaten mit hoher Bioverfügbarkeit und einem in einer speziellen Form vorliegenden Mineralstoff- und Pflanzenextrakt-Mix aufweisen.The invention relates to a pharmaceutical or nutritional supplement for maintaining the health of brain cells and / or the treatment of damaged brain cells by activating the cell metabolism of the brain cells and / or for preventive protection by increasing the concentration of antioxidants in the brain, which is a combination of ingredients with high bioavailability and have a mineral and plant extract mix present in a special form.
Für die Entdeckung des Moleküls Stickstoffmonoxid (NO) wurden 2008 die drei amerikanischen Wissenschaftler Robert F. Furchgott, Ferid Murad und Louis Ignarro mit dem Medizin-Nobelpreis ausgezeichnet.The three American scientists Robert F. Furchgott, Ferid Murad and Louis Ignarro were awarded the Nobel Prize in Medicine for the discovery of the molecule nitrogen monoxide (NO) in 2008.
Diesen Forschern gelang es erstmals, die große Bedeutung des NO für die Blutversorgung von Organen und dessen Rolle als Botenstoff im Organismus nachzuweisen.For the first time, these researchers were able to demonstrate the great importance of NO for the blood supply to organs and its role as a messenger in the organism.
Die kontinuierliche Erzeugung von Stickoxid (NO) ist für die Integrität des kardiovaskulären Systems essentiell. Das Stickoxid (NO) wird in den Endothelzellen der Gefäße durch Abspaltung von der Aminosäure L-Arginin mittels eines Enzyms (NO-Synthase = NOS) und bei Vorhandensein von Sauerstoff in physiologisch normaler Konzentration = Normoxia: normales Sauerstoffniveau im Blut bzw. Körpergewebe - gebildet. Dieser normale Vorgang wird als „NOS dependant pathway“ beschrieben.The continuous generation of nitrogen oxide (NO) is essential for the integrity of the cardiovascular system. The nitric oxide (NO) is formed in the endothelial cells of the vessels by splitting off the amino acid L-arginine by means of an enzyme (NO synthase = NOS) and in the presence of oxygen in a physiologically normal concentration = normoxia: normal oxygen level in the blood or body tissue . This normal process is described as a "NOS dependent pathway".
Bei einigen Herzmedikamenten, wie z. B. dem Nitroglycerin, wird NO enzymatisch von der Substanz abgespalten. Aufgrund seiner kleinen Molekülgröße kann NO dann ungehindert in die Gefäß-Muskelschicht diffundieren (wandern), wo es eine aktivierende Wirkung auf die Guanylatcyclase ausübt. Dieses Enzym bildet den Botenstoff cGMP, der über weitere Schritte eine Erschlaffung der Gefäßmuskulatur bewirkt - das Gefäß erweitert sich.Some cardiac medications, such as B. the nitroglycerin, NO is eliminated enzymatically from the substance. Due to its small molecular size, NO can then freely diffuse (migrate) into the vascular muscle layer, where it has an activating effect on guanylate cyclase. This enzyme forms the messenger substance cGMP, which causes the vascular muscles to relax over the course of further steps - the vessel expands.
Neben der Weitstellung der Gefäße hat NO auch noch andere bekannte Eigenschaften:
- Die erschlaffende Wirkung betrifft nicht nur die Muskulatur der Gefäße, sondern auch die des Bronchialbaums.
- The slack effect affects not only the muscles of the vessels, but also those of the bronchial tree.
NO, das von den Endothelzellen in das Gefäßlumen abgegeben wird, kann die Zusammenlagerung von Blutplättchen verhindern (=Thrombusbildung).NO, which is released from the endothelial cells into the vascular lumen, can prevent platelets from accumulating (= thrombus formation).
Im Nervensystem dient es als wichtiger Signalstoff (Transmitter), der Einfluss auf Gehirn- und Magen-Darm-Funktionen nimmt. So rufen in der Darmwand gelegene Nervenendigungen durch die NO-Ausschüttung eine Relaxierung (Entspannung) der Ringmuskulatur hervor.In the nervous system, it serves as an important signal substance (transmitter) that influences brain and gastrointestinal functions. For example, nerve endings located in the intestinal wall cause relaxation (relaxation) of the circular muscles through the release of NO.
In Abwehrzellen (Makrophagen) wird NO gebildet, dass aufgrund seiner starken „Reaktionsfreudigkeit“ in der Lage ist, Bakterien zu zerstören. Angeregt von Bakterienbestandteilen (z.B. Lipopolysacchariden) produzieren Makrophagen NO in hohen Konzentrationen, so dass lebenswichtige eisenhaltige Enzyme blockiert werden.In defense cells (macrophages), NO is formed, which due to its strong "responsiveness" is able to destroy bacteria. Stimulated by bacterial components (e.g. lipopolysaccharides), macrophages produce NO in high concentrations so that vital iron-containing enzymes are blocked.
In vielen Arealen des ZNS (Zentrales Nerven-System) haben etwa 1-3% der Neurone eine sehr hohe Konzentration von NO-Synthasen (der neuronalen Isoform, nNOS). Da NO etliche Zelldurchmesser weit diffundieren kann bevor es mit einem anderen Molekül reagiert, kann NO so als Neuromodulator wirken. Es kann so auch Neurone beeinflussen, die nicht durch Synapsen miteinander verbunden sind.In many areas of the CNS (Central Nervous System), about 1-3% of the neurons have a very high concentration of NO synthases (the neuronal isoform, nNOS). Since NO can diffuse many cell diameters far before it reacts with another molecule, NO can act as a neuromodulator. It can also influence neurons that are not connected by synapses.
Bei einer reduzierten Sauerstoffkonzentration = Hypoxia wird Stickoxid (NO) nur noch reduziert bzw. unzureichend durch den „NOS“ gebildet. With a reduced oxygen concentration = hypoxia, nitrogen oxide (NO) is only reduced or insufficiently formed by the "NOS".
Die Erfindung trägt zu einer Steigerung der Nitrat (NO3-) und Nitrit (NO2-) Konzentration im Blutplasma und Speichel von Säugetieren bei und ermöglicht so die Bildung von NO ohne die NO-Synthase = „NOS independent pathway“.The invention contributes to an increase in the nitrate (NO3 - ) and nitrite (NO2 - ) concentration in the blood plasma and saliva of mammals and thus enables the formation of NO without the NO synthase = "NOS independent pathway".
Ziel der Erfindung ist, das Allgemeinbefinden / die Lebensqualität deutlich zu verbessern, indem die Gehirnzellen geschützt und/oder ihr Stoffwechsel stimuliert wird und so neue und gesunde Gehirnzellen gebildet werden können. Durch die Blut-Hirn-Schranke passierbare Antioxidantien werden die Gehirnzellen bestmöglich geschützt.The aim of the invention is to significantly improve the general well-being / quality of life by protecting the brain cells and / or stimulating their metabolism and thus new and healthy brain cells being formed. The brain cells are optimally protected by the blood-brain barrier.
Diese Aufgabe wird durch das Arznei- oder Nahrungsergänzungsmittel mit den Merkmalen von Anspruch 1 gelöst. Die Unteransprüche geben vorteilhafte Ausgestaltungen der Erfindung an.This object is achieved by the pharmaceutical or nutritional supplement with the features of claim 1. The subclaims indicate advantageous embodiments of the invention.
Grundgedanke der Erfindung ist es, ein z.B. peroral zu verabreichendes Arznei- oder Nahrungsergänzungsmittel anzubieten, dass neben Kollagenhydrolysat auch Heilpflanzen mit einer hohen Nitrat- und niedriger Oxalatkonzentration z.B. Amaranthus- und/oder Petersilienwurzelextrakt, sowie freies Hydroxyprolin enthält. Es hat sich nämlich herausgestellt, dass die Wirkung des Arzneimittels bzw. Nahrungsergänzungsmittels erheblich verbessert werden kann, wenn zusätzlich zu dem mit dem Kollagenhydrolysat bereitgestellten Hydroxyprolin auch freies Hydroxyprolin sowie Nitrat haltige Heilpflanzen z.B. Amaranthus oder Petersilienwurzel - im Arznei- oder Nahrungsergänzungsmittel enthalten sind. Darüber hinaus kann die Gesundheit der Gehirnzellen durch Antioxidantien, welche die Bluthirnschranke passieren können wie z.B. Astaxanthin und/oder Resveratrol, positiv beeinflusst und ihrem Abbau vorgebeugt.The basic idea of the invention is to use e.g. offer medicinal or nutritional supplements to be administered orally that, in addition to collagen hydrolyzate, medicinal plants with a high nitrate and low oxalate concentration e.g. Amaranthus and / or parsley root extract, as well as free hydroxyproline. It has been found that the effect of the drug or dietary supplement can be significantly improved if, in addition to the hydroxyproline provided with the collagen hydrolyzate, free hydroxyproline and medicinal plants containing nitrate, e.g. Amaranthus or parsley root - contained in the medicinal or nutritional supplement. In addition, the health of the brain cells can be affected by antioxidants that can cross the blood-brain barrier, e.g. Astaxanthin and / or resveratrol, positively influenced and preventing their breakdown.
Bevorzugt besitzt das zur Herstellung des Arznei- oder Nahrungsergänzungsmittels verwendete Kollagenhydrolysat ein Molekulargewicht von kleiner 3,1kD und einen Hydroxyprolingehalt von 11-12%. Dabei ist das Kollagenhydrolysat aus Kollagen vom Typ I, II und/oder III hergestellt.The collagen hydrolyzate used for the production of the pharmaceutical or food supplement preferably has a molecular weight of less than 3.1 kD and a hydroxyproline content of 11-12%. The collagen hydrolyzate is made from type I, II and / or III collagen.
Bevorzugt weist das Arznei- oder Nahrungsergänzungsmittel auch Extrakte von Nitratreichen Heilpflanzen z.B. Amaranthus und/oder Petersilienwurzel in Kombination mit Resveratrol und/oder Curcumin und/oder Astaxanthin auf.The medicinal or dietary supplement preferably also has extracts of nitrate-rich medicinal plants, e.g. Amaranthus and / or parsley root in combination with resveratrol and / or curcumin and / or astaxanthin.
Eine vorteilhafte Zusammensetzung des Arznei- oder Nahrungsergänzungsmittels weist 60-92 Gew.-% Kollagenhydrolysat, 1-10 Gew.-% freies Hydroxyprolin, 1-20 Gew.-% Mineralstoffe, 2-20 Gew.-% Pflanzliche Extrakte und 0,01-5 Gew.-% 3-Acetyl-11-keto-beta-boswellic Säure, jedoch bevorzugt 80-92 Gew.-% Kollagenhydrolysat, 1-5 Gew.-% freies Hydroxyprolin, 0,5-10 Gew.-% Mineralstoffe, 1-10 Gew.-% Pflanzliche Extrakte und 0,01-3 Gew.-% 3-Acetyl-11-keto-beta-boswellic Säure auf.An advantageous composition of the pharmaceutical or nutritional supplement contains 60-92% by weight collagen hydrolyzate, 1-10% by weight free hydroxyproline, 1-20% by weight minerals, 2-20% by weight plant extracts and 0.01 -5% by weight of 3-acetyl-11-keto-beta-boswellic acid, but preferably 80-92% by weight of collagen hydrolyzate, 1-5% by weight of free hydroxyproline, 0.5-10% by weight of minerals , 1-10% by weight of vegetable extracts and 0.01-3% by weight of 3-acetyl-11-keto-beta-boswellic acid.
Besonders bevorzugt ist eine Formulierung des Arznei- oder Nahrungsergänzungsmittels folgender Zusammensetzung:
Für die in der Tabelle vorstehend genannte besonders bevorzugte Formulierung hat sich beim Menschen mit einem Körpergewicht von 75 kg eine 3-malige Einnahme von je 10 g / 8 Stunden insgesamt 30g / Tag als besonders vorteilhaft erwiesen. Selbstverständlich können auch andere Säugetiere mit dem erfindungsgemäßen Arznei- oder Nahrungsmittel behandelt werden. Die vorstehenden Werte sind daher als (vom Körpergewicht oder von anderen physiologischen Parametern abhängige) Richtwerte zu verstehen.For the particularly preferred formulation mentioned in the table above, it has proven particularly advantageous in humans with a body weight of 75 kg to take 10 g / 8 hours a total of 30 g / day. Of course, other mammals can also be treated with the medicament or food according to the invention. The above values are therefore to be understood as guidelines (depending on body weight or other physiological parameters).
Insbesondere bewirkt die tägliche perorale Aufnahme der erfindungsgemäßen Formulierung die Bereitstellung von hochwertigen, da nach einer hohen Bioverfügbarkeit und einer hohen Verdaulichkeit selektierten und kombinierten Nährstoffen, um den Organismus möglichst wenig zu belasten bzw. das Allgemeinbefinden / die Lebensqualität deutlich zu verbessern, indem die Gesundheit von Gehirnzellen aufrecht erhalten und/oder die Behandlung von geschädigten Gehirnzellen durch Aktivierung des Zellstoffwechsels der Gehirnzellen und/oder Reduzierung der Entzündungsparameter und/oder der präventive Schutz der Gehirnzellen durch die Erhöhung der Antioxidantien Konzentration im Gehirn erreicht wird.In particular, the daily oral intake of the formulation according to the invention provides high-quality nutrients, which are selected and combined according to a high bioavailability and a high digestibility, in order to burden the organism as little as possible or to significantly improve the general condition / quality of life by improving the health of Brain cells are maintained and / or the treatment of damaged brain cells is achieved by activating the cell metabolism of the brain cells and / or reducing the inflammation parameters and / or the preventive protection of the brain cells by increasing the antioxidant concentration in the brain.
Claims (8)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102018007480.4A DE102018007480A1 (en) | 2018-09-21 | 2018-09-21 | Medicinal or nutritional supplements for maintaining the health of brain cells and / or treating damaged brain cells by activating the cell metabolism of the brain cells and / or for preventive protection by increasing the antioxidant concentration in the brain. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102018007480.4A DE102018007480A1 (en) | 2018-09-21 | 2018-09-21 | Medicinal or nutritional supplements for maintaining the health of brain cells and / or treating damaged brain cells by activating the cell metabolism of the brain cells and / or for preventive protection by increasing the antioxidant concentration in the brain. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE102018007480A1 true DE102018007480A1 (en) | 2020-03-26 |
Family
ID=69724829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE102018007480.4A Pending DE102018007480A1 (en) | 2018-09-21 | 2018-09-21 | Medicinal or nutritional supplements for maintaining the health of brain cells and / or treating damaged brain cells by activating the cell metabolism of the brain cells and / or for preventive protection by increasing the antioxidant concentration in the brain. |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE102018007480A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT201900024907A1 (en) * | 2019-12-19 | 2021-06-19 | Kolinpharma S P A | Multi-component composition comprising a collagen, resveratrol and astaxanthin and its use for the treatment of tendinopathies |
-
2018
- 2018-09-21 DE DE102018007480.4A patent/DE102018007480A1/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT201900024907A1 (en) * | 2019-12-19 | 2021-06-19 | Kolinpharma S P A | Multi-component composition comprising a collagen, resveratrol and astaxanthin and its use for the treatment of tendinopathies |
| WO2021124253A1 (en) * | 2019-12-19 | 2021-06-24 | Kolinpharma S.P.A. | A multicomponent composition comprising a collagen, resveratrol and astaxanthin and the use thereof for the treatment of tendinopathies |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1982604A1 (en) | Dietary supplement for compensating for a lack of nutrients | |
| EP3506929A1 (en) | Use of collagen hydrolysate for improving endurance performance and for stimulating lipocatabolism | |
| EP2222292A2 (en) | Novel use of omega-3-fatty acid(s) | |
| AT513274B1 (en) | Dietary supplements | |
| DE102018007480A1 (en) | Medicinal or nutritional supplements for maintaining the health of brain cells and / or treating damaged brain cells by activating the cell metabolism of the brain cells and / or for preventive protection by increasing the antioxidant concentration in the brain. | |
| EP3415154A1 (en) | Nasal composition | |
| DE202023001867U1 (en) | Formulation comprising at least one type of cress | |
| DE202009002126U1 (en) | Trace element-containing composition | |
| DE60124516T3 (en) | COMBINATION OF THE LEZITHINE WITH ASCORBIC ACID | |
| WO2020032832A2 (en) | Fortified drinking water | |
| CN111317081A (en) | Beverage with beauty maintaining and young keeping functions | |
| EP0355149B1 (en) | Herbal tea composition and process for producing it | |
| DE102018007482A1 (en) | Medicinal or nutritional supplements for the treatment of COPD and / or for increasing the oxygen saturation (VO2max) and / or for reducing the serum lactate production | |
| EP2508082B1 (en) | Food supplement preparation with amino acids and spice extract | |
| EP1293133B1 (en) | Composition comprising a caffeine-containing substance, particularly guarana | |
| DE69619846T2 (en) | PROPHYLACTIC ABSORBABLE PREPARATION WITH PROTECTIVE EFFECT AGAINST ELECTROMAGNETIC WAVES WITH IONIZING OR NON-IONIZING EFFECT | |
| DE202018101715U1 (en) | Agent for the treatment of neurodegenerative diseases | |
| DE2613078A1 (en) | ASTHMA TREATMENT COMPOSITION | |
| WO2022037951A1 (en) | Composition comprising manuka honey and phycobiliprotein | |
| DE19845314B4 (en) | Procyanidinhaltiges means for the treatment of erectile dysfunction | |
| DE102018007481A1 (en) | Medicinal or nutritional supplements for the treatment and / or prophylaxis of skin and connective tissue diseases and / or inflammatory skin and connective tissue diseases | |
| DE102018131724A1 (en) | Composition and use of the composition as an anti-aging agent | |
| DE102023123064A1 (en) | Antioxidant composition and its use | |
| DE202020107209U1 (en) | Composition containing a combination of amla extract, elderberry extract and nucleotide-containing yeast extract | |
| DE202023103890U1 (en) | Amla fruit extract and nutrient composition containing the same |